Phase I, Open-Label Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2017
At a glance
- Drugs AZD 6738 (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- 15 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 28 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 18 Dec 2015 New trial record